Latest Pro Medicus (ASX:PME) News

Rare earths, lithium and antimony stocks drove the week, while a handful of capital raisings and profit warnings hit hard. The biggest gains came from drilling wins and deal news. The sharpest falls came where investors faced dilution, weaker earnings or takeover friction.

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.

Pro Medicus Limited’s U.S. subsidiary has signed a five-year, A$23 million contract to implement its cloud-based Visage 7 Enterprise Imaging Platform across the University of Maryland Medical System. The rollout is planned to begin immediately, with go-live targeted for early 2027.

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.